SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001213900-23-069125
Filing Date
2023-08-21
Accepted
2023-08-21 07:31:31
Documents
60
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 6-K ea183250-6ka1_altamira.htm   iXBRL 6-K/A 20162
2 UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ea183250ex99-1_altamira.htm   iXBRL EX-99.1 359106
3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea183250ex99-2_altamira.htm EX-99.2 204737
  Complete submission text file 0001213900-23-069125.txt   3493362

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ears-20220630.xsd EX-101.SCH 71379
5 XBRL CALCULATION FILE ears-20220630_cal.xml EX-101.CAL 37813
6 XBRL DEFINITION FILE ears-20220630_def.xml EX-101.DEF 204132
7 XBRL LABEL FILE ears-20220630_lab.xml EX-101.LAB 381186
8 XBRL PRESENTATION FILE ears-20220630_pre.xml EX-101.PRE 216459
54 EXTRACTED XBRL INSTANCE DOCUMENT ea183250-6ka1_altamira_htm.xml XML 326861
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000 41 (0) 41 729 71 94
Altamira Therapeutics Ltd. (Filer) CIK: 0001601936 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 6-K/A | Act: 34 | File No.: 001-36582 | Film No.: 231187334
SIC: 2834 Pharmaceutical Preparations